As of Jun 3, 2026, the Adma Biologics stock's PE ratio is 11.25. This takes into account the latest EPS of $0.69 and stock price of $7.76. The PE ratio marks a decrease of 44% from its last 4 quarters average of 20.0.
The PE ratio of Adma Biologics has averaged 33.25 over the last two years. The current P/E ratio of 11.25 is 66% lower than the historical average. Looking back at the last two years, ADMA's PE ratio peaked in the Jun 2024 quarter at 74.53, when the price was $11.18 and the EPS was $0.15. The lowest point was in the Mar 2026 quarter, when it reached 13.06 with a price of $9.01 and an EPS of $0.69.
Maximum annual increase: 45.79% in 2025
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 29.42 | 45.79% | $18.24 | $0.62 |
| 2024 | 20.18 | N/A | $17.15 | $0.85 |
| 2023 | N/A | N/A | $4.52 | -$0.13 |
| 2022 | N/A | N/A | $3.88 | -$0.33 |
| 2021 | N/A | N/A | $1.41 | -$0.51 |
| 2020 | N/A | N/A | $1.95 | -$0.88 |
| 2019 | N/A | N/A | $4 | -$0.89 |
| 2018 | N/A | N/A | $2.39 | -$1.45 |
| 2017 | N/A | N/A | $3.21 | -$1.91 |
| 2016 | N/A | N/A | $5.12 | -$1.61 |
| 2015 | N/A | N/A | $8.07 | -$1.73 |
| 2014 | N/A | N/A | $11.17 | -$1.81 |
| 2013 | N/A | N/A | $7.8 | -$2.38 |
| 2012 | N/A | N/A | N/A | -$1.39 |
| 2011 | N/A | N/A | N/A | -$16.72 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 13.06 | -55.61% | $9.01 | $0.69 |
| Dec 2025 | 29.42 | 76.59% | $18.24 | $0.62 |
| Sep 2025 | 16.66 | -19.48% | $14.66 | $0.88 |
| Jun 2025 | 20.69 | -8.25% | $18.21 | $0.88 |
| Mar 2025 | 22.55 | 11.74% | $19.84 | $0.88 |
| Dec 2024 | 20.18 | -70.72% | $17.15 | $0.85 |
| Sep 2024 | 68.93 | -7.51% | $19.99 | $0.29 |
| Jun 2024 | 74.53 | N/A | $11.18 | $0.15 |
| Mar 2024 | N/A | N/A | $6.6 | -$0.02 |
| Dec 2023 | N/A | N/A | $4.52 | -$0.13 |
| Sep 2023 | N/A | N/A | $3.58 | -$0.11 |
| Jun 2023 | N/A | N/A | $3.69 | -$0.2 |
| Mar 2023 | N/A | N/A | $3.31 | -$0.24 |
| Dec 2022 | N/A | N/A | $3.88 | -$0.33 |
| Sep 2022 | N/A | N/A | $2.43 | -$0.35 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
The current PE ratio of ADMA is lower than its 3, 5 and 10-year averages.
With a price to earnings (P/E) of 11.25, ADMA ranks lower than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 23.02, Adma Biologics's price to earnings (P/E) is 51% lower.
ADMA's PE ratio stands lower than its peer stock RGEN.
| Stock name | PE ratio | Market cap |
|---|---|---|
| ADMA Adma Biologics Inc | 11.57 | $1.85B |
| RGEN Repligen Corp | 137.61 | $7.14B |
| NVAX Novavax Inc | N/A | $1.67B |
| CVM Cel Sci Corp | N/A | $12.82M |
ADMA's price to earnings ratio is 11.25 as of Jun 3, 2026.
Over the last 3 years, the average price to earnings ratio for ADMA stock is 33.25.
Over the last 5 years, the average price to earnings ratio for ADMA stock is 33.25.
Over the last two years, the Jun 2024 quarter recorded the highest quarterly PE ratio at 74.53.
ADMA's price to earnings ratio is currently 66% below its 2-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jun 3, 2026), Adma Biologics's share price is $7.76. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $0.69. Therefore, Adma Biologics's PE ratio for today is 11.25. PE RATIO(11.25) = STOCK PRICE($7.76) / TTM EPS($0.69)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.